GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $1.53 billion. The enterprise value is $1.57 billion.
| Market Cap | 1.53B |
| Enterprise Value | 1.57B |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 29.97 million shares outstanding. The number of shares has increased by 4.13% in one year.
| Current Share Class | 29.97M |
| Shares Outstanding | 29.97M |
| Shares Change (YoY) | +4.13% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 79.08% |
| Float | 20.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 53.25 |
| PS Ratio | 3.32 |
| Forward PS | 2.85 |
| PB Ratio | 6.25 |
| P/TBV Ratio | 14.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.88.
| Current Ratio | 4.16 |
| Quick Ratio | 3.67 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.01 |
Financial Efficiency
Return on equity (ROE) is -41.36% and return on invested capital (ROIC) is -22.16%.
| Return on Equity (ROE) | -41.36% |
| Return on Assets (ROA) | -7.72% |
| Return on Invested Capital (ROIC) | -22.16% |
| Return on Capital Employed (ROCE) | -13.86% |
| Weighted Average Cost of Capital (WACC) | 13.52% |
| Revenue Per Employee | $354,449 |
| Profits Per Employee | -$85,422 |
| Employee Count | 1,300 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 8.92 |
Taxes
| Income Tax | -159,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.16% in the last 52 weeks. The beta is 1.99, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | -60.16% |
| 50-Day Moving Average | 73.13 |
| 200-Day Moving Average | 69.67 |
| Relative Strength Index (RSI) | 34.88 |
| Average Volume (20 Days) | 1,140,257 |
Short Selling Information
The latest short interest is 6.55 million, so 21.86% of the outstanding shares have been sold short.
| Short Interest | 6.55M |
| Short Previous Month | 6.02M |
| Short % of Shares Out | 21.86% |
| Short % of Float | 31.82% |
| Short Ratio (days to cover) | 8.04 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $460.78 million and -$111.05 million in losses. Loss per share was -$3.76.
| Revenue | 460.78M |
| Gross Profit | 316.85M |
| Operating Income | -63.06M |
| Pretax Income | -111.21M |
| Net Income | -111.05M |
| EBITDA | -36.66M |
| EBIT | -63.06M |
| Loss Per Share | -$3.76 |
Balance Sheet
The company has $170.12 million in cash and $215.38 million in debt, with a net cash position of -$45.27 million or -$1.51 per share.
| Cash & Cash Equivalents | 170.12M |
| Total Debt | 215.38M |
| Net Cash | -45.27M |
| Net Cash Per Share | -$1.51 |
| Equity (Book Value) | 244.69M |
| Book Value Per Share | 8.17 |
| Working Capital | 225.49M |
Cash Flow
In the last 12 months, operating cash flow was -$75.08 million and capital expenditures -$26.14 million, giving a free cash flow of -$101.22 million.
| Operating Cash Flow | -75.08M |
| Capital Expenditures | -26.14M |
| Depreciation & Amortization | 26.40M |
| Net Borrowing | 85.43M |
| Free Cash Flow | -101.22M |
| FCF Per Share | -$3.38 |
Margins
Gross margin is 68.76%, with operating and profit margins of -13.68% and -24.10%.
| Gross Margin | 68.76% |
| Operating Margin | -13.68% |
| Pretax Margin | -24.13% |
| Profit Margin | -24.10% |
| EBITDA Margin | -7.96% |
| EBIT Margin | -13.68% |
| FCF Margin | n/a |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.13% |
| Shareholder Yield | -4.13% |
| Earnings Yield | -7.38% |
| FCF Yield | -6.61% |
Analyst Forecast
The average price target for GeneDx Holdings is $82.00, which is 60.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $82.00 |
| Price Target Difference | 60.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 17.10% |
| EPS Growth Forecast (3Y) | -2.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 2.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.75 |
| Piotroski F-Score | 3 |